$1.98
-0.06 (-2.94%)
Open$2.01
Previous Close$2.04
Day High$2.05
Day Low$1.95
52W High$3.40
52W Low$1.09
Volume—
Avg Volume1.71M
Market Cap227.22M
P/E Ratio—
EPS$-1.19
SectorBiotechnology
Analyst Ratings
Buy
14 analysts
Price Target
+975.8% upside
Current
$1.98
$1.98
Target
$21.30
$21.30
$14.71
$21.30 avg
$34.17
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 23.45M | 43.41M | 87.33M |
| Net Income | -159,250,384 | -265,368,164 | 8.20M |
| Profit Margin | -679.2% | -645.2% | 9.4% |
| EBITDA | -167,444,142 | -294,523,115 | 10.19M |
| Free Cash Flow | — | — | 6.96M |
| Rev Growth | -46.0% | -46.0% | +6.5% |
| Debt/Equity | 0.32 | 0.32 | 0.50 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |